新型降脂药人前蛋白转化酶枯草溶菌素9抑制剂与动脉粥样硬化性心血管疾病、静脉血栓栓塞疾病关系的研究进展  

Research progress on the relationship between the new lipid-lowering drug PCSK9 inhibitor and ASCVD and VTE

作　　者：刘凯[1] 李婧[1] LIU Kai;LI Jing(Clinical College,Wuhan University of Science and Technology,Wuhan,Hubei 430064,China)

机构地区：[1]武汉科技大学临床学院,湖北武汉430064

出　　处：《安徽医药》2022年第11期2141-2144,共4页Anhui Medical and Pharmaceutical Journal

基　　金：湖北省自然科学基金资助项目(2018CFC817)。

摘　　要：随着生活方式的改变,心脑血管疾病逐渐成为全人类死亡的“头号杀手”,高于恶性肿瘤、糖尿病等。血脂的升高尤其是低密度脂蛋白胆固醇(LDL-C)的升高与动脉粥样硬化性心血管疾病(ASCVD)的发生、发展息息相关。现有的专家共识、指南提出他汀类药物是降低LDL-C的一线用药,但仍可能会发生复发性缺血事件。人前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂作为一类新型降脂药,有显著降低血LDL-C水平,同时又可降低脂蛋白(a)的水平,又与ASCVD与静脉血栓栓塞疾病(VTE)的发病可能相关。本文将系统地阐述新型降脂药PCSK9抑制剂与ASCVD、VTE的关系研究进展。With changes in lifestyle,cardiovascular and cerebrovascular diseases have gradually become the"no.1 killer"of all human deaths,higher than malignant tumors and diabetes.The increase in blood lipids,especially the increase in low-density lipoprotein cholesterol(LDL-C)is closely related to the occurrence and development of atherosclerotic cardiovascular disease(ASCVD).Existing expert consensus and guidelines suggest that statins are the first-line drugs for lowering LDL-C,but recurrent ischemic events may still occur.Human proprotein convertase subtilisin 9(PCSK9)inhibitors,as a new class of lipid-lowering drugs,can significantly reduce blood LDL-C levels and reduce lipoprotein(a)levels and are related to ASCVD and venous thromboembolic disease(VTE).This article systematically describes the research progress on the relationship between new lipid-lowering drug PCSK9 inhibitors and SCVD and VTE.

关 键 词：降血脂药物 人前蛋白转化酶枯草溶菌素9 人前蛋白转化酶枯草溶菌素9抑制剂 低密度脂蛋白胆固醇 脂蛋白(a) 动脉粥样硬化性心血管疾病 静脉血栓栓塞症 

分 类 号：R972.6[医药卫生—药品]